Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Muzastotug - Adagene

Next Previous
Drug Profile

Muzastotug - Adagene

Alternative Names: ADG-126; Anti-CTLA-4 monoclonal antibody; Masked anti-CTLA-4 SAFEbody

Latest Information Update: 30 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adagene
  • Developer Adagene; Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Liver cancer; Solid tumours

Most Recent Events

  • 23 Jan 2026 City of Hope Medical Center plans a phase I trial for colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease) in the US (IV) in July 2026 (NCT07363408)
  • 16 Dec 2025 Muzastotug receives Fast Track designation for Colorectal cancer [IV,Infusion] (Combination therapy, Metastatic disease) in USA
  • 16 Dec 2025 Adagene plans a registration trial for Colorectal cancer in 2027

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top